Shots:
Zydus Lifesciences has entered into a strategic licensing, supply & commercialization agreement with Bioeq for Nufymco (ranibizumab), an interchangeable biosimilar to Lucentis, for the US market, marking an expansion of Zydus’ US biosimilar portfolio
Under the agreement, Bioeq will handle development, manufacturing, registration & supply of the finished product while Zydus will lead US…
